The advent of immune checkpoint inhibition (ICI) using antibodies against PD1 and its
ligand PDL1 has prompted substantial efforts to develop complementary drugs. Although …

Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer,
with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. Currently …

In recent years, the introduction of chimeric antigen receptor (CAR) T-cell therapies into
clinics has been a breakthrough in treating relapsed or refractory malignancies in …

Dendritic cells (DCs) play a key role to modulate anti-cancer immunity in the tumor
microenvironment (TME). They link innate to adaptive immunity by processing and …

Hematopoietic progenitor kinase 1 (HPK1), a hematopoietic cell-restricted member of the
serine/threonine Ste20-related protein kinases, is a negative regulator of the T cell receptor …

Protein phosphorylation is an important post‐transcriptional modification involving an
extremely wide range of intracellular signaling transduction pathways, making it an …

Abstract Hematopoietic progenitor kinase 1 (HPK1), a 97-kDa serine/threonine Ste20-
related protein kinase, is a negative regulator of T cells, B cells, and dendritic cells-mediated …

Colorectal cancer (CRC) is among the most common malignant diseases with high morbidity
and mortality rates. Ginseng and its major extracts, ginsenosides, have been used in …

Gastric cancer (GC) and colorectal cancer (CRC) are frequent and aggressive malignancies
worldwide. Despite the emergence of various therapeutic regimens, the prognosis of gastric …

Hematopoietic progenitor kinase 1 (HPK1) is an important negative regulator in T-cell
receptor signaling and as a promising key target for immunotherapy. Herein, based on the …